The Heart Valve Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Heart Valve Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Heart Valve Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Heart Valve Disease and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Heart Valve Disease by eight companies/universities/institutes. The top development phase for Heart Valve Disease is phase ii with four drugs in that stage. The Heart Valve Disease pipeline has seven drugs in development by companies and two by universities/ institutes. Some of the companies in the Heart Valve Disease pipeline products market are: REDNVIA, Spark Biopharma and Rancho Santa Fe Bio.
The key targets in the Heart Valve Disease pipeline products market include Dipeptidyl Peptidase 4, Coagulation Factor X, and Apolipoprotein A.
The key mechanisms of action in the Heart Valve Disease pipeline product include Dipeptidyl Peptidase 4 Inhibitor with two drugs in Phase III. The Heart Valve Disease pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Heart Valve Disease pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Heart Valve Disease overview
Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular heartbeat (heart murmur), dizziness, shortness of breath, and tiredness. The causes of heart valve diseases are most often idiopathic and congenital, but aging and injury can also be a cause. The condition is diagnosed by ECG, 2D echo, chest x-ray, and CT scan. Heart valve diseases are treatable and treatment options include surgery for serious conditions, valvuloplasty, and management with medications.
For a complete picture of Heart Valve Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
